NASDAQ:RAIN

Rain Therapeutics Stock Predictions

etoro logo Buy RAIN
*Your capital is at risk
$2.21
-0.115 (-4.96%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

RAIN Prediction Chart

RAIN Predictions History

Latest community submissions for RAIN.
Predictor Target Session Target Price Result Direction Accuracy Score
Jun 4, 2025 $3.18 +13.70% $3.43 V 92.81% 1
Jun 4, 2025 $3.04 +8.56% $3.43 V 88.62% 1
Jun 4, 2025 Bullish $3.43 V 1
May 1, 2025 $4.24 -4.00% $4.68 X 90.67% 0
May 1, 2025 $4.31 -2.50% $4.68 X 92.08% 0
May 1, 2025 $3.15 -11.76% $4.68 X 67.31% 0
Apr 29, 2025 $2.95 -11.41% $3.57 X 82.63% 0
Jun 12, 2023 $1.45 +17.81% $1.24 V 83.14% 1
Jun 12, 2023 $1.09 -11.13% $1.24 X 88.15% 0
Andre Hayes Andre Hayes @AndreHayes.206897
Jun 12, 2023 Bullish $1.24 X 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for RAIN with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT RAIN THERAPEUTICS INC.
Rain Therapeutics
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinica...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE